Syra Health Awarded Three-Year Public Health Analytics Contract with Mississippi State Department of Health

Syra Health Corp (SYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter ● Syra Health sustained profitability in Q2 2026, following the Company’s first profitable quarter in Q1 2026, delivering net income of $250,242 compared

Scotiabank kept its Sector Outperform rating on Robinhood Markets with a $124 price target, implying a 31.1% upside from the Oct 27 close. The bank cited strong growth in Robinhood's Rothera exchange and strategic customer acquisition as key drivers. Recent analyst price targets for HOOD range from $116 to $165.

Propanc Biopharma (PPCB) aims to begin patient screening for its cancer treatment PPC-001 in February 2027. The Phase 1b study will involve up to 50 patients with solid tumors in Australia. The company is finalizing clinical protocols and site assessments, with regulatory submissions planned for early 2027. PPC-001 has received FDA Orphan Drug Designation for pancreatic cancer.

Evolution Metals & Technologies Corp. (EMAT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Evolution Metals & Technologies Confirms Delivery of All 57 ULVAC Equipment Containers to Pohang Expansion Site, with Commissioning Under Way at the Largest Expected High-Performance Rare Earth Magnet Facility Outside China Equipment secured in months against industr

SELLAS Life Sciences (SLS) completed its Phase 3 REGAL AML trial after reaching 80 deaths, triggering final analysis. The company expects to report preliminary results this quarter. The milestone reduces timing uncertainty for the trial's outcome.

SELLAS Life Sciences (SLS) announced its Phase 3 REGAL trial for galinpepimut-S (GPS) in AML patients reached 80 deaths, triggering final analysis. Results are expected this quarter. GPS targets WT1 protein in various cancers. The company also develops SLS009, a CDK9 inhibitor for AML.